Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease

Por Cheifetz, Adam
Publicado no Gastroenterol Hepatol (N Y) (2017)

Management of Active Crohn Disease

Por Cheifetz, Adam S.
Publicado no JAMA (2013)

Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn’s Disease

Por Papamichael, Konstantinos, Cheifetz, Adam S.
Publicado no J Crohns Colitis (2016)

Use of anti-TNF drug levels to optimise patient management

Por Papamichael, Konstantinos, Cheifetz, Adam S
Publicado no Frontline Gastroenterol (2016)

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy

Por Papamichael, Konstantinos, Cheifetz, Adam S
Publicado no World J Gastroenterol (2017)

Letter: infliximab concentrations during induction therapy - one size doesn’t fit all.

Por Papamichael, Konstantinos, Cheifetz, Adam S.
Publicado no Aliment Pharmacol Ther (2018)

Therapeutic drug monitoring in IBD: for every patient and every drug?

Por Papamichael, Konstantinos, Cheifetz, Adam S.
Publicado no Curr Opin Gastroenterol (2019)

Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives

Por Papamichael, Konstantinos, Cheifetz, Adam S
Publicado no J Crohns Colitis (2020)

The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease

Por Lin, Steven C., Cheifetz, Adam S.
Publicado no Gastroenterol Hepatol (N Y) (2018)

The cost and benefit of anti-TNF therapy from a population perspective—for what it’s worth

Por Frasca, Joseph D., Cheifetz, Adam S.
Publicado no Ann Transl Med (2019)

Varicella Zoster Virus Infection in Patients with Inflammatory Bowel Disease

Por Ham, Maggie, Cullen, Garret, Cheifetz, Adam S.
Publicado em 2013

Etiology and Management of Lack or Loss of Response to Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

Por Fine, Sean, Papamichael, Kostantinos, Cheifetz, Adam S.
Publicado no Gastroenterol Hepatol (N Y) (2019)

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

Por Nanda, Kavinderjit S., Cheifetz, Adam S., Moss, Alan C.
Publicado em 2012

The Role of Mucosal Healing in the Treatment of Patients with Inflammatory Bowel Disease

Por Vaughn, Byron P., Shah, Sveta, Cheifetz, Adam S.
Publicado em 2014

Biologic Concentration Testing in Inflammatory Bowel Disease

Por Vaughn, Byron P., Sandborn, William J., Cheifetz, Adam S.
Publicado no Inflamm Bowel Dis (2015)

Outcomes after Infliximab Therapy Escalation in Ambulatory Patients with Moderately Active Ulcerative Colitis: Infliximab in Ulcerative Colitis

Por Rostholder, Emily, Ahmed, Awais, Cheifetz, Adam S, Moss, Alan C
Publicado em 2012

Varicella Zoster Meningoradiculitis in Crohn’s Disease Treated with 6-Mercaptopurine

Por Cullen, Garret, Krakower, Douglas, Mitty, Jennifer A., Cheifetz, Adam S.
Publicado no Inflamm Bowel Dis (2011)

Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease

Por Papamichael, Konstantinos, Vajravelu, Ravy K., Osterman, Mark T., Cheifetz, Adam S.
Publicado no Dig Dis Sci (2018)

Maintenance adalimumab concentrations are associated with biochemical, endoscopic and histologic remission in inflammatory bowel disease

Por Juncadella, Anna, Papamichael, Konstantinos, Vaughn, Byron P., Cheifetz, Adam S.
Publicado no Dig Dis Sci (2018)

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

Por Lin, Steven C, Goldowsky, Alex, Papamichael, Konstantinos, Cheifetz, Adam S
Publicado no Inflamm Bowel Dis (2019)